It is good strategy here for the reason you cite AND the fact that it becomes a slightly more attractive takeover. Nexafed is a product that may slowly grab pseudoephedrine shelf space, a fixed commodity from a pharma like McNeil occupying the space with druggist cards for Sudafed and the private labels of the same product like CVS and Target. They will not let the space go easily, particularly with a product that is stored on the shelf (why wait in line for the druggist?). That is what's happening. Limited shelf space. . . who get's it. IMO sellers should see an off-the-shelf availability as an advantage as opposed to having potential buyers requiring a druggist counter service.
So. . . ACUR may be purchased if market share trends up significantly or Nexafed is licensed to place McNeil or another licensee "back on the shelf" with perhaps private label rights to preserve their Target, Costco, Walgreens, et. al. space and market share. If buyers have a choice, they will look at the card, look at the drug counter waiting line, and buy the Nexafed. It just needs to be accessible.